Aspirin Associated With Reduced Mortality in Patients With CRC

May 29-June 2, 2015; Chicago, Illinois
The largest cohort ever to examine the effects of aspirin as secondary prevention reveals that aspirin independently reduces the risk of both CRC-specific mortality and all-cause mortality.
Format: Microsoft PowerPoint (.ppt)
File Size: 378 KB
Released: June 1, 2015


Educational grant provided by:
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Novartis Pharmaceuticals Corporation

Related Content

Expert review of key data in GI cancers from the 2021 ASCO annual meeting, from Clinical Care Options (CCO)

Manish A. Shah, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 27, 2021 Expired: July 26, 2022

Gain clinical insights quickly with this short slideset from Clinical Care Options (CCO) on key actionable biomarkers for GI cancers

David H. Ilson, MD, PhD John L. Marshall, MD Eric Van Cutsem, MD, PhD Released: July 23, 2021

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for colorectal cancer (CRC)

Eric Van Cutsem, MD, PhD Released: July 15, 2021

Final analysis from KEYNOTE-177 of first-line pembrolizumab vs chemotherapy in patients with MSI-H/dMMR metastatic CRC from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.